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1. Introduction 
This chapter revisits established and emerging information on the causes of the human 
Neural Tube Defects (NTD). These congenital malformations, affecting 1 per 1000 births, 
have adverse consequences that afflict society as well as the affected individuals. The 
mechanisms by which they arise are still unknown.  
Investigators have focused their efforts in many research fields (developmental and 
metabolic pathways and animal models) to understand the mechanisms underlying the 
etiology of these devasting defects. Nevertheless, few candidate genes have proved to have 
significant impact on the development of NTDs. Moreover, the existing body of literature is 
still fragmented and constrained by limited size, lack of power, and lack of replicated and 
independent studies.  
The review attempts to describe the results obtained by the analysis of candidate genes from 
three types of evidences: developmental pathway and biochemical pathways (folate 
metabolism). The update of the literature includes the most recent findings.  
This chapter aims to improve the knowledge of the readers on a such complex multifactorial 
disease outlining that, even though the remarkable recent progresses, further studies are 
needed to clarify the molecular basis of NTDs.  
The knowledge of the etiology con help us in developing strategies for prevention of the 
NTDs, by the identification of parents who have a higher chance of having an affected child. 
In these families it may be possible to clarify the mode of inheritance and estimate the 
recurrence risk of the disorder. Actually, we are far to have immediate clinical benefits for 
NTDs, but providing clinicians with a better knowledge of the development of the disease, 
we could speed up the search for a focused prevention and a more complete familial 
counselling. 
Neural tube defects (NTDs) are congenital malformations that involve failure of the neural 
tube closure during the early phases of development at any level of the rostro-caudal axis. 
The incidence of NTDs in European countries excluding UK and Ireland was 0.1-0.6 per 
1000 births in the period 1989-2002. [1] Each year, more than 4500 pregnancies in the 
European Union are affected by NTDs. [2]  
www.intechopen.com
 
Neural Tube Defects – Role of Folate, Prevention Strategies and Genetics 
 
142 
In order to gain insights into the embryonic basis of NTDs, it is important to understand the 
morphogenetic processes and the underlying molecular mechanisms involving the neural 
tube closure. Neurulation begins with formation of the neural plate, a thickening of the 
ectoderm on the dorsal surface of the post-gastrulation embryo. Neurulation occurs in a 
two-part process: i) primary neurulation (weeks 3-4) resulting in formation of the neural 
tube that will develop into brain and most of spinal cord; ii) secondary neurulation (weeks 
5-6) that creates the neural tube caudal to the mid-sacral region. [3] During the primary 
neurulation, the neural plate is subject to shaping and folding, with fusion along the midline 
to form the tube. The secondary neural tube is derived from a population of mesenchymal 
cells, the tail bud, which undergo proliferation and condensation followed by cavitation and 
fusion with the primary neural tube. [4] Neurulation is driven by redundant mechanisms 
both at the tissue and cellular level. [5]. Active processes required for neural tube closure 
include convergent extension cell movements, expansion of the cranial mesenchyme, 
contraction of actin filaments, bending of the neural plate, and adhesion of the neural folds. 
Insight into these mechanisms are being provided by the many mouse models in which 
NTDs occur as a result of genetic mutations. [6] Neural tube closure is a discontinuous 
process and proceed bi-directionally in a zipper-like fashion. Five closure sites exist in 
human embryos and on the basis of the study of clinical cases, van Allen et al. [7] proposed 
a multisite model in which the initial site of closure starts at the rhomboencephalic segment 
and the caudal end is the last to close. 
There are several different types of NTDs. The distribution of different types may vary in 
different populations and can also vary by the birth prevalence of the defects. [8] The 
most common classification includes anencephaly, myelomeningocele (also called spina 
bifida) and encephalocele. Craniorachischisis and iniencephaly are considered to be rarer 
in most populations. NTDs group includes other conditions, broadly described as occult 
spinal dysraphisms (lipoma, tight filum terminale) and some complex dysraphic states as 
diastematomelia, spinal segmental dysgenesis, and caudal regression syndrome. [9] 
Failure of the closure at any level of the body axis leads to open NTDs where the affected 
nervous tissues are exposed to the surface. Failure of the secondary neurulation leads to 
closed forms of NTDs, where the defect is covered by the skin and it is not exposed to the 
surface of the body.  
The majority of NTD cases are non syndromic or isolated NTDs, meaning that the NTD is 
the only defect. A number of anomalies including clubfoot, deformation of the lower limbs, 
hydrocephalus and Arnold Chiari II malformation have been widely accepted as secondary 
abnormalities that may accompany NTDs. Aetiology of non syndromic NTDs is 
multifactorial with both environmental and genetic factors implicated. Non syndromic 
NTDs have an important genetic component and it is important that research is focused at 
determining the basis of this genetic aetiology. The aim of this chapter is provide evidences 
for genetic contribution to non syndromc NTDs along with the discussion of different 
approaches for identifying such genes. The identification of genetic factors for NTDs is a 
relatively a new area of research. In fact, thare are many different mutations in mice 
resulting in NTDs, but only few well characterized genetic factors in humans. Here we 
provide an overview of the major causative genes and the more recent genetic advances 
emerging thanks to the powerful tool of mouse models.  
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2. Evidence for genetic contribution of non syndromic NTDs 
There are strong evidence supporting a genetic component to NTDs. NTDs can be 
associated with various chromosome rearrangements, the most common include trisomy 13, 
trisomy 18, tetraploidy, and deletions involving chromosomes 2, 3, 11, 13, 22. Genetic 
syndromes with NTDs include Meckel-Gruber syndrome and Currarino syndrome. [10] 
Overall hereditabilty in NTDs is estimated to be 60% with multiple genes involved. 
Recurrence risk for sibling is 2-5%, which represents up to 50-fold increased risk respect to 
that observed in the general population [11]. Positive family history families with many 
affected children have implied an autosomal recessive model of inheritance. [12] Inspection 
of multiplex families demonstrated that affected relative pairs are related at either the 
second- or third-degree, suggesting oligogenic inheritance. [13]. The recurrence risk and the 
inheritance pattern in families have been demonstrated to follow a multifactorial threshold 
model in which the liability to these malformations follows a normal distribution pattern: 
additive effects of several genetic and environmental factors cumulate to increase the liability 
until a threshold value beyond which the phenotype become expressed. Twin studies 
demonstrated that concordance rate is relatively low among cotwins of affected cases. [11]. 
Recurrences in families in which the case is affected with spina bifida tend to be spina bifida 
and families; recurrence in families in which the case is anencephaly tend to be anencephaly. 
[14-15] However, one third of recurrent cases involve a NTDs phenotype that is different from 
the cases phenotype. This intra-familial heterogeneity may be the consequence of the 
pleiotropic effect of a underlying causative gene. NTD occurrence vary among different ethnic 
groups and it is unknown if this population-specific incidence is due to differences in the 
frequency of risk-associated alleles or to specific dietary habits or exposures. The highest 
incidence is in Northern China (7/1000) and the lowest in Japan (0.1/1000). In Europe, the 
highest rate is reported in Ireland (3/1000). Furthemore, an Irish study demonstrated that 
predisposing genetic factors may be transmitted from the mother’s side of the family. [16] 
Another important line of evidence for a genetic basis for NTDs comes from the numerous 
mouse models, both spontaneous and induced via a gene-driven process. [17].  
3. Identification of susceptibility genes involved in NTDs 
The number and identity of genes predisposing to NTDs remain unknown. Once genes 
implicated in the development of NTDs are identified, it will be essential to understand 
potential additive or multiplicative effects of genetic and environmental factors. Candidate 
genes for NTDs can be classified into two categories according to how they have been 
identified: biological and positional. Candidate genes based on biological plausibility have 
resulted from research done in animal models and from biological pathways important for 
NTDs. Candidate genes can also be identified through positional techniques via 
chromosomal rearrangements in NTD patients or genomic screen in linkage analysis.  
A number of genes have been identified from research done in experimental animals, most 
notably from mouse models. The mouse model remains one of the most well studied animal 
models for NTDs. More than 190 genes in mouse produce varying NTDs phenotypes. [17]. 
There are both naturally occurring and induced strains of mice. The two most common 
mouse phenotypes are exencephaly, that is comparable to human anencephaly, and 
craniorachoischisis, in which the neural tube remains open along the entire body axis. The 
mouse system is useful for the study of NTDs because the genetic map of mouse is noted 
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and many of the human homologues are known. Moreover, mouse has a short gestational 
period and does not require the same ethical considerations as the studies in humans. 
Another advantage is that both genetic and environmental factors may be studied. For 
example three mouse mutants have been demonstrated to have a reduced risk for NTDs 
after maternal folate supplementation: crooked (Cd), splotch (Sp) and cartilage homeoprotein1 
(Cart1). [17] Nevertheless, there are obvious differences between mouse and human, so that 
it is possible that genes contributing to NTDs in mouse not always do the same in humans. 
The majority of human NTDs are isolated a show a multifactorial inheritance. In contrast, 
NTDs in mouse are a lethal condition in the homozygous knock-out state and NTDs is a part 
of a larger syndrome. Mice have a four-sites model of neural tube closure. In humans 
controversies have been arisen about the number of closure sites , although there is a general 
agreement on the presence of rostral and caudal sites. The majority of candidate genes from 
mouse are involved in a wide range of functions, in crucial steps of neurulation and only few 
are implicated in cellular functions such as genome stability and DNA repair. Despite a such 
long list of candidate genes, studies failed to show positive association in humans. Another 
system that can be used is the zebrafish (Brachydanio rerio), that is a cost-effective model system 
for studying NTDs since fertilized eggs can develop rapidly into transparent embryos, 
allowing all stages of vertebrate development to be visualized easily. [18] Zebrafish has proven 
to be very useful for studying embryological processes, including morphogenesis, lineage 
specification, and mechanisms of acquired cell fate. Furthemore, assays have been developed 
to perform both gain and loss of function experiments. Partial loss of function phenotypes can 
be generated by microinjection of antisense morphplino. [19] A forward genetic approach 
(random mutagenesis) will led to identification of potential NTDs genes. Such a screen would 
be useful in expanding the collection of potential NTDs risk genes. 
The approach for identifying positional candidate genes is through a genomic screen in 
which genetic markers at known locations are tested in families with two or more affected 
individuals. Thanks to advances in the density and polymorphisms of genetic markers, 
highthroughput genotyping methods, and powered statistical genetic linkage analysis, it is 
possible to perform large-scale investigation of human complex traits such as NTDs. 
Regions with excess sharing of alleles among affected individuals are considered region of 
interest and may harbour genes that predispose to NTDs. Few studies have performed 
genome-wide linkage studies in families with multi le affected individuals, given the 
scarcity of these large families. In fact, high morbidity and mortality rates associate with the 
disorder, and pregnancy termination after case identification are factors that limit the 
ascertainment of multiplex families. [20] A recent genomic screen was performed on 44 
multiplex American NTDs families identifying linkage to chromosome 7 and 10. Two 
candidate genes (Meox2 and Twist1 ) were identified on chromosome 7 and three 
candidates (FGFR2, GFRA1, Pax2) were found on critical region of the chromosome 10. [21] 
Statistical test are employed to assess evidence of allelic association for NTDs. Infact 
allelic association is population-specific. There are two methods of testing allelic 
association in NTDs candidate genes: case-control and family-based studies. 
Traditionally, NTDs studies have employed case-control studies, where the allelic 
frequency in an unrelated group of patients are comparated to a group of controls 
individuals. This study can be flawed, if the controls are not properly matched with 
patients for age, gender, and geographic origin. This population admixture may result in 
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biased results and spurious associations. In family based studies, the frequencies of alleles 
transmitted by a parent to the affected child are compared with that of the allele not 
transmitted. The family studies can also detect a paternal or maternal effect. The most 
used family-based test is the Transmission disequilibrium test (TDT). [22] When one 
parent is not available for the analysis unaffected sibling can be used as controls. 
Association studies in patients with NTDs were often underpowered by a small sample 
size, leading to inconsistent results. Larger cohorts of patients and controls are needed to 
reach definitive conclusion regarding the role of the most of studied genes. Meta-analysis 
for variants of genes are also warrented.  
4. Genetic variations in folate metabolism 
A large number of experimental and observational clinical research studies over the past 
half century demonstrated that folic acid supplementation decreases both the occurrence 
and recurrence risk of NTDs by approximately 70%. [23-24] The recommended intakes are 4 
mg/day for high risk women and 0.4 mg/day for all others. Maternal periconceptional 
folate supplementation may act to overcome insufficient maternal folate levels. However, in 
most cases, mothers of affected foetuses have either normal folate status or are, at most, 
mildly folate-deficient, arguing against maternal folate deficiency as a major causative 
factor. [25-26] Alternatively, it is postulated that supplemental folic acid may act to 
overcome an underlying defect in folate metabolism that results from a genetic mutation in 
the mother or in the foetus. Although a protective effect of folate is recognized, the 
mechanism by which some women develop low folate levels and predispose their offspring 
to NTDs and other congenital malformation is still debated.  
 
Fig. 1. Folate and homocysteine metabolism 
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Folic acid is a water soluble B vitamin that partecipates in transfer of single-carbon units in 
several critical pathways (Figure 1). These pathways include synthesis or catabolism of 
amino acids (serine, glycine, histidine, and methionine) and synthesis of nucleotides. 
Through their role in methionine synthesis, folates are also critical for the methylation cycle, 
since methionine is the methyl donor for many important methylation reactions, including 
DNA methylation. Folate-dependent conversion of homocysteine to methionine begins early 
in development in all tissues and provides a link between folate and homocysteine 
metabolism. An elevation of plasma homocysteine, mild hyperhomocysteinemia, has 
become recognized as a risk factor for NTDs [25, 27].  
Proteins that mediate, or are functionally associated with, folate metabolism have provided 
candidates for genetic analysis in human NTDs. There are over 25 proteins involved in the 
folate and closed-related homocysteine pathways. Several of the corresponding genes have 
been examined as risk factors for NTDs, but few have showed a positive association (Table 1).  
Variant Association with NTDs risk 
MTHFR C677T + 
MTHFR A298C +/- 
MTHFR C116T + (only in one study) 
MTHFR G1793A + (only in one study) 
MTHFD1 G19658A + 
MTHHD1L 781-6823ATT(7-9) + 
MTR A2756G - 
MTRR A66G 
+ (in mothers with low levels of 
vitamin B12) 
CBS 844ins68 + 
BHMT G742A + 
RFC-1 A80G + 
FR alpha/Betas + 
TCII A67G; G280A; A701G; C776G; C1043T; G1196A + 
GCPII C1561T - 
Table 1. Variants of genes involved in folate and homocysteine metabolism studied for 
association with NTDs risk 
Methylenetetrahydrofolate reductase (MTHFR) converts 5,10methyleneTHF to 5-mthylTHF, 
the methyl donor for homocysteine conversion to methionine. The 677CT variant converts 
an alanine residue to a valine residue. Biochemical studied confirmed that this variant is 
characterized by residual activity after heating. [28] The variant is extremely common, with 
homozygosity frequencies ranging between 5% and 15% in many populations. [29] The 
association of the mutant 677T/T genotype with hyperhomocysteinemia occurs only in 
individuals with low folate status. Folate has been shown to stabilize the mutant human 
enzyme and should prevent hyperhomocysteinemia in mutant individuals [30]. The MTHFR 
677T/T Homozygous mutant genotype first emerged as a possible risk factor for NTDs in 
some populations [31-33], even if other studies failed to demonstrate an association. [34-35] 
Two meta-analysis were performed in 1997 [36] and 2000 [29]. The latter study found a 
pooled odds ratio for cases 677T/T homozygous cases of 1.7 (95%CI 1.4-2.2), with a pooled 
attributable fraction of NTDs cases of 6%. A second mutation in the MTHFR gene 
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(1298AC) has also been positively associated with NTDs [37-39]. The 1298 variant is in 
strong linkage disequilibrium with the 677 variant, such that 1298C and 677T changes are 
rarely seen on the same allele. Therefore, the two mutations can occur on separate alleles in 
the same individual who may be predisposed to hyperhomocysteinemia, if folate status is 
low. Compound heterozygosity for the 677T and 1298C alleles (677C/T/1298A/C) has been 
suggested to increase the risk, although the results have been conflicting. [37, 40-41] 
Moreover, a very recent report identified other two polymorphisms of MTHFR gene a 
116CT (P39P) and 1793GA (R594Q). A possible association between NTDs cases and 
these two new polymorphisms was found; further analysis demonstrated that this 
association is driven by the linkage disequilibrium with the 677CT NTD risk factor [42]. 
The MTHFR 677 variant has been suggested to account for approximately 10% of the NTDs 
risk. [29]. Since up to 70% of NTD cases may be prevented by the folate, other variants in 
folate-related genes have to be involved. 
Given its important role in folate metabolism, the trifunctional enzyme 
methylenetetrahydrofolate dehydrogenase/methenyltetrahydrofolate cyclohydrolase/ 
formyltetrahydrofolate synthetase (MTHFD1) may play a role in NTD pathogenesis. Brody et 
al. demonstrated that the polymorphism 1958GA (R653Q) within the MTHFD1 gene 
resulting in the substitution of a conserved arginine by glutamine is a maternal risk factor for 
NTDs. [43] Mothers who possess two copies of the Q allele have an increased risk of an NTD-
affected pregnancy. There was also a suggestion that the Q allele decreases fetal viability. Very 
recently, the impact of the MTHFD1 1958G>A polymorphism on NTD risk was elevaluated in 
the Italian population both by case-control and family-based studies. An increased risk was 
found for the heterozygous 1958G/A (OR=1.69; P=0.04) and homozygous 1958A/A (OR=1.91; 
P=0.02) genotypes in the children. The risk of an NTD-affected pregnancy of the mothers was 
increased 1.67-fold (P=0.04) only when a dominant effect (1958G/A or 1958A/A vs 1958G/G) 
of the 1958A allele was analysed. Family-based tests also confirmed a significant excess of 
transmission of the 1958A allele to affected individuals, demonstrating that this variant is a 
genetic risk factor for Italian NTD cases. [44] A potential role of the mitochondrial paralogue 
MTHFD1L as candidate gene for NTDs association has been also investigated. In particular, a 
common triallelic deletion/insertion variant 781-6823ATT(7-9) which influences splicing 
efficiency was tested and a significant incresead risk for allele 1 [ATT(7)] was identified. [45] 
The methionine synthase (MTR), a vitamin B12-dependent enzyme, utilizes 5-
methyltetrahydrofolate, generated by MTHFR, for homocysteine remethylation to 
methionine. A polymorphism of the MTR gene, the 2756AG (D919G) that lead to the 
substitution of an aspartic acid with a glycine residue, has been studied in several studies, 
but the majority have not reported a significant association [36, 40, 46-48].  
A common variant in the gene methionine synthase reductases (MTRR), the 66AG (I22M), 
that converts a isoleucine into a methionine residue, has been shown to confer a four-fold 
increased risk for NTDs in mothers having low vitamin B12 levels [49]. Other studies have 
also suggested an effect on NTDs risk, both for mothers and children with 66GG mutant 
genotype, but interactions with nutrients has not been examined. [50-51]. The MTRR mutant 
genotype combined with MTHFR mutant genotype conferred a significant four-fold 
increased risk in children [49]. An interaction of MTR and MTRR genotypes has also 
recently reported. [50]  
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Cystathionine beta synthase (CBS) catalyzes the first step in the transsulfuration pathway of 
homocysteine. The 68-bp insertion in the exon 8 of the gene appeared to be associated with 
an increased risk in several studies. [46, 52-53]. Multiplicative interaction of the CBS 68-bp 
insertion with the homozygosity for the MTHFR 677CT variant was showed to confer a 
five-fold increased risk for NTDs children, The MTHFR mutation alone had a two-fold 
increased risk, whereas there was no risk for CBS mutant genotype alone. [54].  
Betaine homocysteine methyltransferase (BHMT) catalyzes homocysteine remethylation to 
methione, using betaine as the methyl donor. Homozygosity for the BHMT R239Q variant is 
associated with a decreased risk in mother and children [55]. The 80GG genotype for the 
80AG variant of the reduced folate carrier (RFC1), which transports 5-
methyltetrahydrofolate across the plasma membrane, confers an increased risk for mothers 
with low red blood cell folate [55] and for children whose mothers do not use vitamins [56]. 
A recent study by Rothenberg et al. showed that some mothers with a NTDs-pregnancy 
produce autoantibodies that bind to folate receptors (FRs) on the placental membrane [57] 
The authors suggest that folate supplementation would bypass autoantibody formation that 
mediates the placental FRs blockage.  
Several variants have been identified in trancobalamin II (TCII) gene (67AG, 280GA, 
701AG, 776CG, 1043CT, 1196GA), but none of the SNPs were associated with a 
significant increased risk for NTD. Among them, three TCII SNPs (67AG, 776CG, 
1196GA) affected the transcobalamin concentration, even if these variants only partially 
accounted for the reduced proportion of vitamin B12. [58].  
The glutamate carboxypeptidase II (GCPII) is localized in the jejunum and catalyzes the 
conversion of folate polyglutamates to monoglutamates prior to absorption. The GCPII 
C1561T (H475Y) variant was identified and studied as risk factor for NTDs, but no study 
demonstrated an association. [59-60]  
In general, there are many different polymorphism in genes invoved in folate transport or 
metabolism that have been identified and studied for association with NTDs risk, but data 
are not yet convincing for most of them. The only one well characterized genetic risk factor 
is the MTHFR C677T. Many studies are biased by small sample size and insufficient 
statistical power. The interaction between genes and non genetic factors is an intriguing area 
of investigation, but it requires larger cohort of patients and controls (Table 2).  
MS A2756G/MTHFR C677T (Morrison et al., 1998) 
MS A2756G/MTRR A66G (Zhu et al., 2003)
MTRR A66G/MTHFR C677T (Relton et al., 2004) 
MTRR A66G/FGCP C1561T (Relton et al., 2004) 
MTRR A66G/MTHFD1 G1958A (van der Put et al., 1997; Hol et al., 1998) 
MTHFR A1298C/RFC-1 A80G (DeMarco et al., 2003) 
RFC-1 A80G/CBS 844ins68 (Relton et al., 2004) 
MTFR C677T/CBS 31 bp VNTR (Afman et al., 2003) 
MTHFR C677T/CBS 844ins68 
(Botto and Mastroiacovo 1998; de Franchis 
et al. 2002;Relton et al., 2004) 
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5. From animal models to humans 
Mouse mutant strains that exhibit NTDs have arisen by spontaneous mutations, or are the 
result of mutagen- and gene-trapped induced mutations. Other mutants have arisen 
through manipulation of an already identified and characterized gene that is manipulated to 
alter its function. The majority of the known mouse models are those generated by gene 
knock-out technology, that mainly develop cranial defects. [17, 61-62] The penetrance of 
NTDs in mouse models is frequently affected by both genetic background and 
environmental influences. Mouse mutant genes produce NTDs, for the most part, when they 
are homozygous. Mouse with double heterozygosity for two mutant genes also develop 
NTDs, demonstrating that gene-gene interaction may promote the development of NTDs. 
[63] A variety of exogenous agents when administrated to embryos exert teratogenic effects 
with production of abnormalities that include NTDs. Drugs, chemicals, or other substances 
extraneous to pregnancy cause NTDs. In addition, molecules derived from maternal 
metabolism, such those produced in maternal diseases condition, may induce NTDs. For 
example, elevated glucose and ketone body concentrations, as found in diabetes mellitus, 
increased the NTD risk. [64] Teratogens interact directly with genetic mutant effects in the 
causation of NTDs. The frequency of exencephaly in the curly tail strain is elevated by 
administration of all-trans retinoic acid. [65] This demonstrates that exogenous agents can 
exacerbating the severity of the phenotype interacting with a genetic mutation. An 
exogenous agent that ameliorates the genetic predisposition to NTDs in mouse models is a 
candidate therapeutic agent. Several NTDs mouse mutant, Sp, Cart1, Cd, Splotch, have 
shown to interact with folic acid, exhibiting a reduction of NTDs incidence. [66-68] But not 
all mouse models are folate responsive, demonstrating that there is a proportion of NTDs 
defects that require another preventive therapy. Inositol was shown preventive in folate-
resistante mouse models, such as curly tail strain, an action that operates via stimulation of 
protein kinase C activity. [69] 
Many of the genes that are mutated or disrupted in NTD mouse models are now being 
identified. Few genes have been identified as contributing to human NTD aetiology. 
Recently, animal models demonstrated an essential role of for the planar cell polarity (PCP) 
signaling pathway in the process of the convergent extension. Sistematic analysis of human 
homologues PCP genes is giving promising results for our understanding of molecular basis 
of human NTDs.  
6. Genes of PCP pathway and NTDs 
Several studies showed that early, during embryogenesis of CNS, the major driving force 
essential to the shaping of the neural plate is a process which is referred to as convergent 
extension (CE). This is a morphogenetic process by which cells elongate medio-laterally and 
intercalate with other neighboring cells forming a longer and narrower array. This changes 
lead to the conversion of an initially wide and short neural plate into a narrow and 
elongated one. [70] A crucial role in CE has been assigned to the Planar Cell Polarity (PCP) 
pathway, a highly conserved, non-canonical Wnt-frizzled-dishevelled signaling cascade 
(Figure 2). PCP signaling plays a key role in establishing and maintaining polarity in the 
plane of epithelia in Drosophila and in epithelial and non-epithelial tissues in vertebrates. 
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[71-72] Genetic studies of mutants affecting complex structures in the fly have identified a 
group of proteins referred to as “core PCP” components, that include transmembrane 
proteins such as Frizzled (Fz), Strabismus/Van Gogh (Stbm/Vang) and Flamingo (Fmi), as 
well as cytoplasmic proteins, including Dishevelled (Dsh/Dvl), Prickle (Pk), and Diego 
(Dgo). [73-74] Downstream of the core PCP members, additional factors mediate the PCP 
signaling in different tissues, the so-called “PCP effectors”, that include the proteins 
Inturned, Fuzzy and Fritz. [75-77] Evidence for the involvement of the PCP pathway in CE 
process in vertebrate has emerged from studies of a wide range of mutants of orthologs of 
Drosophila PCP genes in several animal models such as zebrafish, Xenopus and mouse. [78-
83] In mouse, Loop-tail (Lp) was the first mutant to implicate a role of PCP pathway and CE 
process in NTD pathogenesis. [84-85] Lp heterozygotes are characterized by a “looped” tail 
appearance, while homozygotes develop a severe NTD resembling human 
craniorachischisis. [86] NTD in Lp is caused by independent missense mutations S464N (Lp) 
and D255E (Lpm1Jus), localized in the proposed C-terminal cytoplasmic domain of a gene, 
now referred to as Van Gogh-like 2 (Vangl2). [84-85; 87] A novel experimentally induced 
allele, Lp (m2Jus), having a missense mutation, R259L, in Vangl2 has been recently reported. 
This mutation segregates in a recessive manner, with all heterozygotes appearing normal, 
and 47% of homozygotes showing a looped-tail. Homozygous Lp (m2Jus) embryos showed 
spina bifida in 12%. [88] Seven other mutant mice carrying mutations in some of PCP genes 
and fail to complete neural tube closure leading to craniorachischisis have been described; 
they include: circle-tail (Crc), crash (Crsh), Ptk7, and dishevelled1-/-/dishevelled2-/- (Dvl1-/-/Dvl2-
/-), Frizzled3-/-/Frizzled6-/- (Fzd3-/-/Fzd6-/-), dishevelled3/Lp (Dvl3+/-/Lp/+) double-knockout 
mice, and Fuzzy. [89-94] The Crsh mouse harbors a mutation in Celsr1 that encodes a protein 
orthologous to Drosophila Flamingo. [93] Like Vangl2, this gene functions in the PCP 
pathway. In the Crc mouse, a point mutation was identified introducing a stop codon into 
the apical cell polarity gene scribble (Scrb1), a PDZ domain-containing gene that is the 
ortholog of Drosophila scribble. [95] Scribble was not known, at a first time, to be a PCP 
component in Drosophila. However, a polarity defect is observed in the inner ear of the Crc 
mice, suggesting a role for Scrb1 in establishment of polarity in vertebrates. [96] A mutation 
in the protein tyrosine kinase 7 (Ptk7) gene, wich encodes a conserved transmembrane 
protein with tyrosine kinase homology, disrupts neural tube closure and stereociliary 
bundle orientation and shows genetic interaction with Lp. [93] Double null homozygous 
embryos for both dishevelled1 and dishevelled2 genes (Dvl1-/-/Dvl2-/-) as well as Frizzled3 
and Frizzled6 genes (Fzd3-/-/Fzd6-/-), two members of highly homologous seven-pass 
receptor family, also exhibit NTDs that closely resemble the craniorachischisis observed in 
single knock-out mice. [91, 97] Although neurulation appeared normal in both Dvl3-/- and 
LtapLp/+ mutants, combined mutants Dvl3+/-/LtapLp/+ displayed incomplete neural tube 
closure. [94] Fuzzy knockout mice exhibit both NTDs and defective primary cilia. [98] The 
exact mechanism by which the PCP pathway regulates CE cellular movements remains 
poorly understood. A recent study reported that PCP signalling was requested for re-
establishing cell polarity that is transiently lost in dividing cells during neurulation. In fact, 
during mitosis, dividing cells loose their polarized features threatening the overall 
organization of the developing tissue; PCP signaling acts through quickly repolarization of 
the daughter cells and directs their integration into the neuroepithelium. [99] Evidence for 
an intrinsic role of ciliogenesis in PCP is derived from study of Bardet-Biedl syndrome 
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(BBS), a genetically heterogeneous human disorder with pleiotropic manifestations 
including obesity, polydactily, endocrine dysfunction, cystic renal disease, progressive 
photoreceptor degeneration and hearing loss. [100-101] BBS genes share the common 
features that the encoded proteins localized to the cilium or its cellular anchor, the basal 
body. [102] Targeted disruption of Bbs1, Bbs4 or Bbs6 in mouse lead to phenotype shared 
with PCP mutants, including NTDs (14% of Bbs4-/- mice display exencephaly) [103]. A 
second link between PCP and cilia has come from the identification of the mouse Inversin 
(Invs) gene, which encodes a large adaptor-like protein with homology to Drosophila PCP 
protein Diego. Recent studies in zebrafish and Xenopus embryos revealed that knock-down 
of Invs disrupts CE process. [104] The subcellular localization of inversin is complex and 
dynamic, and includes the basal bodies, primary cilia and, during metaphase and anaphase, 
the spindle poles. [105-107] A recent study in Xenopus demonstrated a link between 
ciliogenesis, Hedgehog signalling (HH) and PCP [108]. Disruption of orthologs of two 
Drosophila PCP effectors, Inturned (In) and Fuzzy (Fy), leads to failure of ciliogenesis, 
resulting from incorrect orientation of ciliary microtubules. In Xenopus, the absence of In 
and Fy elicited prominent rostral NTDs in addition to more caudal NTDs, predicted to 
result from disruption of PCP signalling. These caudal defects were shown to arise from 
failure of CE in the neural plate, whereas the rostral defects were shown to stem from a 
failure of Hedgehog signalling. [108]. Finally, it is tempting to speculate that both PCP and 
Hedgehog phenotypes may be linked in humans to NTDs. Mutations in two genes, MKS1 
and MKS3, that were predicted to be involved in cilia formation have been recently found in 
patients with Meckel syndrome (MKS), characterized by bilateral renal cystic dysplasia, 
central nervous system malformations, bilateral upper and lower limb polydactyly and 
fibrocystic changes of the liver. [109-112]. The gene mutated in type 1 MKS encodes a 
protein associated with the base of the cilium in vertebrates and nematodes. Loss of function 
of mouse Mks1 results in an accurate model of human MKS, with structural abnormalities in 
the neural tube, biliary duct, limb patterning, bone development and the kidney that mirror 
the human syndrome. Analysis of patterning in the neural tube and the limb demonstrates 
altered Hedgehog pathway signaling underlies some MKS defects.[113] 
7. PCP pathway and human NTDs 
In humans mutations in VANGL1 and VANGL2 genes cause NTDs and abrogate the 
physical interaction between VANGL proteins and other members of PCP pathway. In a 
first study three Italian patients who were heterozygotes for missense mutations of 
VANGL1 (V239I, R274Q, and M328T) were identified. The V239I mutation was identified in 
a girl with a severe form of caudal regression The girl's mother also carried the mutation, 
but showed no clinical signs of NTDs. Her brother having a milder form of the disorder, a 
dermal sinus, also carried the V239I mutation. The V239I mutation was absent in the father, 
in the maternal aunt and in the maternal grandparents, indicating that it had arisen de novo 
in the germline of one of the maternal grandparents or somatically in the mother, with 
subsequent transmission through the mother's germline. Valine at position 239 is located in 
the fourth predicted transmembrane domain of the VANGL1 protein. It is invariant and part 
of a 'VLLE' motif, which is conserved across all known VANGL proteins. In vitro studies 
demonstrated that V239I mutation abrogated interaction between VANGL1 and their 
binding partners, Dvl1, Dvl2, and Dvl3. The R274Q mutation was found in a girl with 
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myelomeningocele. Her mother, who carried the R274Q mutation, and maternal aunt had 
vertebral schisis, a minimal sign of NTD. Arg274 is in the cytoplasmic domain of VANGL1 
and is invariant in all known orthologs except in C. elegans, in which it is replaced by 
glutamate. The M328T mutation was carried by a child with myelomeningocele, 
hydrocephalus, and Chiari II malformation. M328T mutation occurs in the predicted 
cytoplasmic domain of VANGL1. We did not detect these variants in 150 ancestrally 
matched controls. Thus, these are the first genetic mutations clearly linked to NTDs such as 
spina bifida in humans. [114].  
 
Fig. 2. Planar Cell Polarity (PCP) pathway.  
Wnt proteins bind to its receptors, Frizzled (Fz), leading to recruitment and activation of 
Dishevelled, that is a multimodule protein PCP activation requires formation of a 
multimodule protein-complex including two transmembrane proteins, Vangl (1/2) and 
Flamingo/Celsr, and three cytoplasmic proteins, Dishevelled, Diego and Prickle. These 
proteins acquire an asymmetric localization at the plasma membrane that is crucial for 
proper PCP signaling. Scribble is a cytoplasmic protein binds to and genetically interacts 
with Vangl, suggesting a role in PCP signaling. Ptk7 receptor is a regulator and shows 
genetic interaction with Vangl. Downstream effectors include small GTPases Rho or Rac, 
which are active when bound to GTP. The Formin homology protein, Daam1, as an 
important link between Dishevelled and the Rho GTPase for cytoskeletal modulation. 
Alternatively, Dvl can initiate Rac signaling and its downstream effector c-Jun N-terminal 
kinase (JNK) that promote sites of actin polymerization modulating lamellipodia extension. 
Inturned (In) and Fuzzy that are down-stream regulator of PCP pathway do influence 
convergent extension and they also are broadly required for Hedgehog (HH) signaling 
www.intechopen.com
 
Advances in Genetics of non Syndromic Neural Tube Defects 
 
153 
Validation of the potential pathogenic effect of VANGL1 V239I, M328T, and R274Q mutations 
in vivo was performed by investigating their effect on CE in zebrafish. Knocking down the 
expression of tri, the ortholog of Vangl2, using an antisense morpholino (MO), led to a 
defective CE manifested by a shortened body axis and widened somites. Co-injection of the 
human VANGL1 with the tri-MO was able to partially rescue the tri-MO induced phenotype 
in zebrafish. In contrast, co-injection of V239I and M328T, failed to rescue this phenotype. 
Overexpression studies evaluating the ability of the human VANGL1 alleles to induce a CE 
phenotype when injected at high doses in zebrafish embryos have been carried out. While 
overexpressing the wild-type allele led to a severely defective CE, overexpression of either 
V239I and M328T variants failed to do so. Thus, results from both tri-MO knockdown/rescue 
results and overexpression assays suggest that these two variants most likely represent "loss-
of-function" alleles that affect protein function during embryonic development. [115].  
Overall, human VANGL1 gene has been sequenced in a cohort of 810 NTD patients with 
various ethnic origin. Eight missense mutations both in familial (V239I, R274Q, S83L, and 
R181E) and sporadic (M238T, F153S, L202F, and A404S) cases have been identified. These 
mutations affect evolutionary conserved amino residues that are distributed along the entire 
length of the VANGL1 protein. Since these many of these variants do not represent obvious 
null mutations (like stop codon, deletions), functional experiments are needed to investigate 
their effect on the protein function. All mutations detected so far in VANGL1 in NTDs are 
heterozygous, leading to the speculation that these variants may act as partial loss of 
function alleles and interact with other environmental and genetic factors to cause the NTD 
phenotype. The finding of VANGL1 mutations in both open and closed NTDs support this 
hypothesis of common underlying molecular mechanisms. [116] 
Sequencing of VANGL2 in the same cohort of patients led to the identification of six novel 
heterozygous missense mutations in seven patients, that could be pathogenic based on 
genetic and initial validation data [117]. Four of these mutations, R135W, R177H, L242V, 
R270H, were predicted to be damaging to protein function using bioinformatics' tools, and 
two others, T247M and R482H, affect highly conserved residues across evolution. Five 
mutations were identified in patients affected with closed spinal NTDs, suggesting that 
VANGL2 mutations may predispose to NTDs is approximately 2.5% of closed spinal NTDs. 
A Chinese study recently reported the identification of three other missense mutations in 
VANGL2 in fetuses with a cranial NTDs: S84F, R353C , and F437S. [118] 
Recently, three non-synonymous Fuzzy amino acid substitutions in some patients with 
NTDs have been identified, resulting in alteration of the length of primary cilia and cell 
movement. Since Fuzzy knockout mice exhibit both NTDs and defective primary cilia and 
Fuzzy is expressed in the emerging neural tube, mutations in Fuzzy may account for a 
subset of NTDs in humans. [98] 
Thus, the evidence is accumulating for an important contribution of PCP genes to the 
pathogenesis of human NTDs, necessitating a detailed analysis of other not yet explored 
PCP genes in large cohorts of patients.  
8. Conclusions 
NTDs are a group of severe congenital malformations having a profound physical, 
emotional, and financial effects on families and communities. Despite their importance in 
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terms both of human suffering and cost to the health care system, the causes of most cases of 
NTDs are not known. There is growing evidence that many NTDs have a genetic 
background. Elucidation of genetic causes predisposing to NTDs are important challenge in 
light of preconception care program that aim to reduce reproductive risks before conception 
and to improve the chance for a healthy birth outcome. Further, the genetic screening done 
for research setting may become available for diagnostic purposes, allowing to identify the 
predisposition before conception and to provide reproductive options to minimize the 
chance of having affected children in the future. 
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